The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
TriLite, the developer of the world's smallest projection display, has successfully completed an extended Series A funding round, raising its total Series A funding to more than ?20 million. This ...
Apple's on-device generative AI capability is a unique competitive advantage powered by Apple Silicon. Read why I have an ...
no other medicine has outperformed Keytruda in a late-stage lung cancer study — one reason why Merck’s therapy has become one of the most lucrative pharmaceutical products in the decade since ...
Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe. The European ...
Since 2004, I have worked on PCMag’s hardware team, covering at various times printers, scanners, projectors, storage, and monitors. I currently focus my testing efforts on 3D printers, pro and ...
What all these products have in common is that they're the best photo scanners in their respective categories on the market today. For more on what to look for in a scanner, check out our top ...
Our list of best-selling baby products is fun as well as functional, and generally a lifesaver for totally exhausted parents who don’t have the time to test out dozens of products to find the best one ...
Credit: R Photography Background/Shutterstock. Merck & Co has received European Commission (EC) approval for the use of Keytruda (pembrolizumab ... recommendation from the Committee for Medicinal ...
Its four-year dividend yield is 2.90%. MRK’s sales for the second quarter ended June 30, 2024, increased 7.2% year-over-year to $16.11 billion, while its KEYTRUDA product sales improved by 15.9% from ...